公开(公告)号：US07745462B2

公开(公告)日：2010-06-29

申请号：US10552023

申请日：2004-04-02

Applicant: Robin Alec Fairhurst ,  David Andrew Sandham ,  David Beattie ,  Ian Bruce ,  Bernard Cuenoud ,  Reamonn Madden ,  Neil John Press ,  Roger John Taylor ,  Katharine Louise Turner ,  Simon James Watson

Inventor： Robin Alec Fairhurst ,  David Andrew Sandham ,  David Beattie ,  Ian Bruce ,  Bernard Cuenoud ,  Reamonn Madden ,  Neil John Press ,  Roger John Taylor ,  Katharine Louise Turner ,  Simon James Watson

IPC: A61K31/02 ,  C07D215/38

CPC classification number: C07D215/227 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14

Abstract: Compounds of formula I in free or salt form, wherein —C—Y—, R1 and R2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Abstract translation: 游离或盐形式的式I化合物，其中-C-Y-，R 1和R 2为G具有本说明书中指出的含义，可用于治疗通过活化2-肾上腺素受体而预防或缓解的病症 。 还描述了含有化合物的药物组合物和制备该化合物的方法。

公开(公告)号：US20070066607A1

公开(公告)日：2007-03-22

申请号：US10552023

申请日：2004-04-02

Applicant: Robin Fairhurst ,  David Sandham ,  David Beattie ,  Ian Bruce ,  Bernard Cuenoud ,  Reamonn Madden ,  Neil Taylor ,  Roger Taylor ,  Katharine Turner ,  Simon Watson

Inventor： Robin Fairhurst ,  David Sandham ,  David Beattie ,  Ian Bruce ,  Bernard Cuenoud ,  Reamonn Madden ,  Neil Taylor ,  Roger Taylor ,  Katharine Turner ,  Simon Watson

IPC: A61K31/541 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/496 ,  A61K31/4709 ,  C07D265/36 ,  C07D417/02 ,  C07D413/02 ,  C07D403/02

CPC classification number: C07D215/227 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14

Abstract: Compounds of formula I free or salt form, wherein —C—Y—, R1 and R2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Abstract translation: 式I的游离或盐形式的化合物，其中-CY-，R 1和R 2是G具有说明书中指出的含义，可用于治疗 通过β2 - 肾上腺素受体的激活而被预防或缓解。 还描述了含有化合物的药物组合物和制备该化合物的方法。